Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P R Lowenstein

Showing results (121-130 of 123) with videos related to

Pageof 13
Sort By:
You have reached the last page of results.This site can display upto 123 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2005
Regulatable gene expression systems for gene therapy applications: progress and future challengesS Goverdhana, M Puntel, W Xiong, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Clinical Pharmacology and Therapeutics|February 19, 2010
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastomaA K M G Muhammad, M Puntel, M Candolfi, et al.
Pageof 13

Showing results (121-130 of 123) with videos related to

Sort By:
Pageof 13
You have reached the last page of results.This site can display upto 123 results.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 11, 2005
Regulatable gene expression systems for gene therapy applications: progress and future challengesS Goverdhana, M Puntel, W Xiong, et al.
Journal of Virology|December 17, 2008
Herpes simplex virus type 1 thymidine kinase sequence fused to the lacz gene increases levels of {beta}-galactosidase activity per genome of high-capacity but not first-generation adenoviral vectors in vitro and in vivoM Puntel, R J Barrett, S Mondkar, et al.
Clinical Pharmacology and Therapeutics|February 19, 2010
Study of the efficacy, biodistribution, and safety profile of therapeutic gutless adenovirus vectors as a prelude to a phase I clinical trial for glioblastomaA K M G Muhammad, M Puntel, M Candolfi, et al.
Pageof 13